Skimmianine

Skimmianine is a furoquinoline alkaloid derived primarily from plants in the Rutaceae family, including Skimmia japonica and Ruta graveolens. It exerts biological activity chiefly through acetylcholinesterase inhibition and induction of apoptotic pathways in cancer cell lines.

Origin & History

Skimmianine is a furoquinoline alkaloid (4,7,8-trimethoxyfuro[2,3-b]quinoline) found primarily in plants of the Rutaceae family, including Skimmia japonica, Zanthoxylum species, and Aegle marmelos. It occurs as a secondary metabolite in leaves, bark, and roots, synthesized through a complex pathway beginning with anthranilic acid.

Historical & Cultural Context

Rutaceae plants containing skimmianine have been used in traditional medicine systems, particularly Aegle marmelos (Bael tree) in Ayurvedic medicine for bark and leaf remedies. While the plants have longstanding folk use in South Asian medicine, specific historical documentation of skimmianine itself as an isolated compound is not available.

Health Benefits

• Anticancer activity demonstrated in vitro against ovarian cancer (A2780) and other cell lines (K562, Colo38) - evidence quality: preliminary (cell studies only)
• Acetylcholinesterase inhibition potentially supporting cognitive function - evidence quality: preliminary (in vitro studies)
• Anti-inflammatory effects shown in preclinical models - evidence quality: preliminary (animal/cell studies)
• Antimicrobial and antiparasitic properties demonstrated in laboratory tests - evidence quality: preliminary (in vitro only)
• Potential cardiovascular and antidiabetic effects noted in preclinical research - evidence quality: preliminary (no human data)

How It Works

Skimmianine inhibits acetylcholinesterase (AChE), the enzyme responsible for breaking down acetylcholine at synaptic junctions, thereby potentially prolonging cholinergic neurotransmission. In cancer cell models, it promotes apoptosis through activation of caspase cascades and modulation of Bcl-2 family protein expression, reducing cell viability in lines such as A2780 (ovarian), K562 (leukemia), and Colo38 (melanoma). Additionally, skimmianine demonstrates anti-inflammatory activity by suppressing NF-κB signaling and downregulating pro-inflammatory cytokines including TNF-α and IL-6.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on skimmianine. All available research is limited to preclinical studies, with pharmacological activities reviewed in PMID 36518041 calling explicitly for human clinical studies to validate preliminary findings.

Clinical Summary

All current evidence for skimmianine is derived from in vitro cell studies and preclinical animal models; no human clinical trials have been published to date. In ovarian cancer cell line A2780, skimmianine reduced cell viability in a dose-dependent manner, with IC50 values reported in the low micromolar range in some assays. Rodent studies suggest mild anxiolytic and sedative-adjacent effects at doses of approximately 10–30 mg/kg, though translating these findings to human dosing remains speculative. The overall evidence quality is preliminary, and skimmianine cannot currently be recommended for any clinical indication.

Nutritional Profile

Skimmianine is a naturally occurring furoquinoline alkaloid (molecular formula C14H13NO4, molecular weight 259.26 g/mol), not a conventional food nutrient and therefore carries no macronutrient, vitamin, mineral, or fiber content. It is a pure bioactive secondary metabolite isolated primarily from plants of the family Rutaceae, notably Skimmia japonica, Ruta graveolens, Zanthoxylum species, and Dictamnus albus. As a compound rather than a whole food ingredient, its 'nutritional profile' is defined entirely by its phytochemical identity: a tricyclic furoquinoline skeleton with methoxy substituents at positions 4, 7, and 8, contributing to its lipophilic character (estimated LogP ~1.8–2.2). Concentrations in source plants vary: bark and root extracts of Zanthoxylum species have yielded skimmianine at approximately 0.01–0.1% dry weight depending on extraction method and plant part. Bioavailability data in humans is absent; preclinical pharmacokinetic studies suggest moderate oral absorption due to its lipophilic nature, with hepatic first-pass metabolism likely involving cytochrome P450 enzymes (CYP3A4 implicated based on structural analogs). It is not a source of calories, protein, carbohydrates, or fats. No dietary reference intake or tolerable upper limit has been established. Present in trace amounts in some herbal preparations but not quantified as a nutritional component in any regulatory food database.

Preparation & Dosage

No clinically studied dosage ranges are available as no human trials have been conducted. Oral activity has been noted in animal studies, but standardization details, extract concentrations, and safe dosing parameters remain undetermined. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Berberine, dictamnine, γ-fagarine, magnoflorine, xanthoplanine

Safety & Interactions

Skimmianine's safety profile in humans has not been formally established through controlled trials, making definitive risk assessment impossible at this time. Because it inhibits acetylcholinesterase, combining skimmianine with cholinergic drugs, anticholinergics, or other AChE inhibitors such as donepezil or rivastigmine could produce additive or antagonistic pharmacodynamic interactions. Rutaceae-derived alkaloids as a class have shown phototoxic potential in some studies, suggesting possible photosensitivity risk with topical or high-dose oral exposure. Skimmianine should be avoided during pregnancy and lactation due to complete absence of safety data, and individuals with liver conditions should exercise caution given hepatic alkaloid metabolism.